Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.
You may also be interested in...
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
Clovis Transitions To Commercial Stage On Rubraca Approval
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy
AstraZeneca hopes "robust" data from its Phase III SOLO-2 trial will pave the way for its PARP-inhibitor Lynparza (olaparib) to be used in the US market as a maintenance therapy in BRCA-mutated second-line ovarian cancer. But some analysts think FDA may want more proof before giving the okay.